[Monitoring of heparin therapy during extracorporeal bypass: what are the remaining questions?].
Cardiac surgery with extracorporeal circulation induces major alterations of haemostasis and requires high level of anticoagulation, usually achieved by unfractionated heparin infusion. Optimization of anticoagulant regimen, through adapted biological monitoring, can probably improve postoperative course, at least for postoperative haemostatic status. Despite increasing knowledge on extracorporeal circulation-induced haemostatic abnormalities and the development of new biological devices for heparin monitoring, the optimal level of anticoagulation remains matter of debate, as well as the monitoring procedures. This critical review presents the current available data on heparin anticoagulation and monitoring in this specific context, and underlines the pending issues about anticoagulation management during extracorporeal bypass.
Jude
B
B
Institut d'hématologie biologique et d'hémobiologie-transfusion, CHRU de Lille, boulevard du Professeur-Leclercq, 59037 Lille, France. b-jude@chru-lille.fr
Lasne
D
D
Mouton
C
C
de Moerloose
P
P
D000925:Anticoagulants / Q000008:administration & dosage / Q000097:blood / Q000627:therapeutic use*; D006348:Cardiac Surgical Procedures; D001026:Coronary Artery Bypass; D004351:Drug Resistance; D005112:Extracorporeal Circulation; D006487:Hemostasis / Q000502:physiology; D006493:Heparin / Q000008:administration & dosage / Q000097:blood / Q000627:therapeutic use*; D006801:Humans; D016343:Monitoring, Intraoperative
D000925:Anticoagulants; D006493:Heparin